অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 0.216 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; magnesium stearate; citric acid; sodium citrate dihydrate - temgesic sublingual tablets are indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; lactose monohydrate; povidone; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; citric acid; pregelatinised maize starch; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

মাল্টা - ইংরেজি - Malta Medicines Authority

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - mannitol - solution for infusion - mannitol 200 mg/l - blood substitutes and perfusion solutions

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: sodium starch glycollate type a; meglumine; lactose monohydrate; sodium hydroxide; maize starch; microcrystalline cellulose; mannitol; magnesium stearate; povidone; iron oxide red - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: microcrystalline cellulose; sodium hydroxide; maize starch; magnesium stearate; povidone; sodium starch glycollate type a; lactose monohydrate; meglumine; mannitol; iron oxide yellow - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: lactose monohydrate; mannitol; maize starch; sodium starch glycollate type a; povidone; magnesium stearate; sodium hydroxide; meglumine; microcrystalline cellulose; iron oxide red - telmisartan hct mylan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

icu medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema; - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) . no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to mat

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg); levodopa, quantity: 200 mg - tablet, uncoated - excipient ingredients: iron oxide red; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate; mannitol; pregelatinised maize starch; docusate sodium; ethylcellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 5 mg; empagliflozin, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; mannitol; crospovidone; titanium dioxide; magnesium stearate; copovidone; pregelatinised maize starch; macrogol 6000; iron oxide red; maize starch - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).